A Phase 3 interventional study of Dexmedetomidine in Breast Cancer, sponsored by Institut Curie. Recruiting at 3 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.
Sponsored by Institut Curie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing dexmedetomidine in Breast Neoplasms — 3 open to participants now, 3 under way, 1 of them phase 3. Dexmedetomidine · Breast Neoplasms.
Among the 14 studies testing dexmedetomidine in Breast Neoplasms, this one is the 3rd largest by planned enrollment, is the only one that started in 2022, is one of 3 in phase 3, and was the 9th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →3 of the 14 studies testing dexmedetomidine in Breast Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
United States Naval Medical Center, Portsmouth · Sites in United States
Ages 18+ · Healthy volunteers
Al-Azhar University
Ages 20–60 · Women only
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 158 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 94 across the 14 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 10 most frequent:
Institut Curie is the lead sponsor of 135 studies on the registry; 29 are open to participants now.
35 studies in Breast Neoplasms by Institut Curie: 7 open now, 7 under way, 2 of them phase 3. Of 25 finished, 0 (0%) have results posted.
Among the 35 studies in Breast Neoplasms by Institut Curie, this one is the 14th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 3, and was the 27th registered.
Institut Curie’s Breast Neoplasms studies by the year they started, since 2006.
1 of the studies testing dexmedetomidine in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05439005Phase 3Institut CurieOpioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study. | 2027-06-06 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing dexmedetomidine in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Institut Curie’s 35 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will compare morphine consumption during the first 48 hours postoperatively between the OFA group and the CA control group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
OFA (Opioid Free Anaesthesia) group:
Drug: Dexmedetomidine
CA (Conventional Anaesthesia) control group:
Dexmedetomidine+Lidocaine
comparison of Morphine consumption in the two groups
Time frame: during the first 48 hours postoperatively
Assessment of vasopressor requirement and total intraoperative filling volume
Time frame: end of surgery
Assessment of the state of consciousness on arrival in the PACU
Time frame: on arrival in the PACU
Assessment of the incidence of PONV in the PACU, at D0, D1 and D2
Time frame: in the PACU, at D0, D1 and D2
Maximum VAS at rest and mobilization in the PACU, at D0, D1 and D2
Time frame: in the PACU, at D0, D1 and D2
Dose of morphine given in titration in the PACU (mg)
Time frame: in the PACU
Number of boluses demand on PCA during the first 48 hours postoperatively
Time frame: the first 48 hours postoperatively
DN3 score (Neuropathic Pain 3) on D2, D4, M1, M3 and M6
Time frame: on D2, D4, M1, M3 and M6
Length of stay in PACU (h) and length of in-hospital postoperative length of stay (D)
Time frame: at discharge
Assessment of the flap failure rate (flap removal surgery) and flap micro-anastomosis re-exploration rate
Time frame: at discharge
Pain management satisfaction scores (score from 0 to 10) at discharge
Time frame: at discharge
Collection of serious adverse events between D0 (date of surgery) and D30
Time frame: between D0 (date of surgery) and D30
Dose of intraoperative rescue remifentanil in the OFA group (mcg)
Time frame: at discharge
Morphine consumption during the first 48 hours post-operatively (mg) in each breast reconstruction subgroup (immediate and secondary);
Time frame: the first 48 hours postoperatively
Plan to share: Yes — Investigators will share de-identified data sets with interested researchers, educators or clinicians. Materials generated under the project will be disseminated in accordance with Institut Curie policies.
Time frame: Data requests can be submitted starting 9 months after article publication and will be made accessible for up to 12 months.
Access criteria: Access to trial individual participant data can be requested by qualified researchers engaging in independent scientific reserach, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a data sharing agreement (DSA).
Started Dec 2022 (actual). Primary completion is estimated for Jun 2027, 53 months after the start.
Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 53 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine